Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$6.00 ▼ -0.20
(-3.23%)
MKT CAP: $664.8M • VOL: 1.13M
52W L $4 52W H $11
ROARABLE / RQD
E • 26/100
PIOTROSKI
1 / 9
SLDB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $501.8M | $363.2M |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$179.2M | -$129.7M |
| Operating Margin % | — | — |
| Net Income (GAAP) | $0 | $0 |
| EBITDA (Normalized) | -$178.3M | -$129.2M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$156.3M | -$100.0M |
| Capital Expenditures (CapEx) | $1.2M | $654.0K |
| Free Cash Flow (FCF) | -$157.4M | -$100.7M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $59.9M | $80.2M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $180.0M | $137.2M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SLDB.